Background

As a general rule, antibiotics are more polar, and larger than the majority of drug compounds.  These properties bring with them unhelpful absorbance properties and pharmacokinetic profiles.  The EligoChem technology confers the ability to design and select compounds which, although polar, are well absorbed and is ideally suited for the discovery and optimization of novel antibiotics.

What is the EligoChem advantage for Antibiotic drug discovery and optimisation?

The chemical space accessed by the EligoChem libraries and designs, aligns with known antibiotic drug space. Antibiotics are generally more polar, and have more hydrogen bond donors and acceptors than found in typical drug sets. These properties often bring with them undesirable absorbance properties and pharmacokinetic profiles.

The EligoChem technology confers the ability to design and select compounds which, although polar, are well absorbed and thus we believe is ideally suited to the discovery and optimization of novel antibiotics.

The amphiphilic nature of the EligoChem compounds, provides property flexibility to navigate the complex barriers found in bacterial membranes.

Drug set = representative of typical pharma screening collection